Interleukin To Hold Investor Meeting On June 12 Following Annual Meeting
04/09/2007
INTERLEUKIN GENETICS TO HOLD INVESTOR MEETING
ON JUNE 12 FOLLOWING ANNUAL MEETING
WALTHAM, MA – April 9, 2007 – Interleukin Genetics, Inc. (AMEX: ILI) will hold an Investor Meeting in New York City on Tuesday, June 12 at 12:00 p.m. ET, after the conclusion of the company’s annual meeting, scheduled for the same day.
Interleukin will provide an overview of the operations of its businesses and discuss its go-forward strategy and key goals at the meeting. The Company also expects to be able to comment on the search to identify a new chief financial officer. Interleukin previously engaged leading executive search firm Korn/Ferry International to assist in the search for a seasoned financial professional with public company experience to fill the role of CFO.
The investor meeting will be broadcast live on the Internet via the Interleukin corporate website at www.ilgenetics.com at 12:00 p.m. ET on June 12. To access the live webcast presentation, please go to the website at least 10 minutes early to register and to download and install any necessary audio software. The webcast replay of the presentation can be accessed at the Interleukin corporate website within approximately two hours following the conclusion of the live event.
Information about the meeting can also be obtained by contacting Weber Shandwick, J.J. Rissi at (212) 445-8224, or The Financial Relations Board, Rich Tauberman at (201) 964-2408.
About Interleukin
Interleukin Genetics, Inc. is a company focused on developing, acquiring, and commercializing personalized health products that can help individuals improve and maintain their health through preventive measures. It uses functional genomics to help in the development of risk assessment tests based on the genetic variations in people. The Company also develops and markets nutritional and OTCeutical® products. Interleukin has commercialized genetic tests for periodontal disease risk assessment, cardiovascular risk assessment, and general nutrition assessment. In addition, through its Alan James Group subsidiary which it acquired in August 2006, Interleukin sells its nutritional product brands, including Ginkoba®, Ginsana®, and Venastat® through the nation’s largest food, drug and mass retailers. The Company’s current development programs focus on osteoporosis and weight management genetic risk assessment tests, as well as its new proprietary OTCeuticals for distribution through Alan James Group. The Company expects that these programs will also lead to the personalized selection of nutritional products, and provide consumers and healthcare professionals with better. For more information about Interleukin and its ongoing programs, please visit http://www.ilgenetics.com.
Certain statements contained herein are “forward-looking” statements including statements regarding our ability to develop diagnostic, personalized nutritional and therapeutic products to prevent or treat diseases of inflammation and other genetic variations, our ability to screen nutritional compounds for their effects on inflammatory responses and other genetic variations, given specific genetic patterns, and our ability to make progress in advancing our core technologies. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, the risk of market acceptance of our products, the risk of technology and product obsolescence, delays in product development, the performance of our commercial partners, the availability of adequate capital, the actions of our competitors and other competitive risks, our ability to integrate acquired businesses, our ability to maintain relationships with our important customers, and those risks and uncertainties described in our annual report on Form 10-K for the year ended December 31, 2006, as amended, filed with the Securities and Exchange Commission, our quarterly reports on Form 10-Q and other filings made by us with the Securities and Exchange Commission. We disclaim any obligation or intention to update these forward-looking statements.
For Interleukin Genetics:
Paul Voegelin (781) 398-0700
Additional Contacts for Media / Investors:
J.J. Rissi (212) 445-8224, Weber Shandwick
Rich Tauberman (201) 964-2408, Financial Relations Board
  |